The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CAMP | -60.72% | N/A | N/A | -61% |
| S&P | +13.96% | +91.24% | +13.85% | +17% |
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.80M | 0.0% |
| Gross Profit | $0.38M | 194.8% |
| Gross Margin | 47.67% | 0.0% |
| Market Cap | $60.48M | 0.0% |
| Market Cap / Employee | $1.10M | 0.0% |
| Employees | 55 | 0.0% |
| Net Income | -$15.10M | -12.0% |
| EBITDA | -$12.74M | 2.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $75.26M | 2876.9% |
| Accounts Receivable | $1.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.09M | -51.4% |
| Short Term Debt | $3.25M | -0.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -99.11% | 0.0% |
| Return On Invested Capital | -75.55% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.22M | 0.0% |
| Operating Free Cash Flow | -$11.22M | 0.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.66 | 1.28 | 0.57 | 1.51 | - |
| Price to Sales | 9.72 | 21.52 | - | ||
| Price to Tangible Book Value | -0.66 | 1.28 | 0.57 | 1.51 | - |
| Enterprise Value to EBITDA | -3.66 | -3.10 | 0.21 | -1.01 | - |
| Return on Equity | -172.7% | - | |||
| Total Debt | $8.73M | $7.96M | $7.22M | $6.35M | -34.17% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
